Hologic — Nov 4, 2024 release

• On October 14, 2024, the Company announced its agreement to acquire Gynesonics, Inc., a privately held medical device company focused on the development of minimally invasive solutions for women’s health for approximately $350 million, subject to adjustment, as the Company seeks to broaden its surgical portfolio. The Company anticipates closing this acquisition in the first half of calendar year 2025. Completion of the acquisition is subject to customary closing conditions, including receipt of required regulatory approvals. Key financial results for the fiscal fourth quarter are shown in the table below.     GAAP   Non-GAAP       Q4’24   Q4’23   Change Increase (Decrease)   Q4’24   Q4’23   Change Increase (Decrease)   Revenues   $987.9   $945.3   4.5%   $987.9   $945.3   4.5%   Gross Margin   56.5%   52.9%   360 bps   61.5%   60.4%   110 bps   Operating Expenses   $327.6   $367.8   (10.9%)   $311.0   $303.7   2.4%   Operating Margin   23.3%   14.0%   930 bps   30.0%   28.3%   170 bps   Net Margin   18.1%   9.6%   850 bps   24.0%   23.2%   80 bps   Diluted EPS   $0.76   $0.37   105.4%   $1.01   $0.89   13.5%